Cite
Milton CI, Selfe J, Aladowicz E, et al. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. Mol Oncol. 2021;doi: 10.1002/1878-0261.13145.
Milton, C. I., Selfe, J., Aladowicz, E., Man, S. Y. K., Bernauer, C., Missiaglia, E., Walters, Z. S., Gatz, S. A., Kelsey, A., Generali, M., Box, G., Valenti, M., de Haven-Brandon, A., Galiwango, D., Hayes, A., Clarke, M., Izquierdo, E., Gonzalez De Castro, D., Raynaud, F. I., Kirkin, V., & Shipley, J. M. (2021). FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. Molecular oncology, . https://doi.org/10.1002/1878-0261.13145
Milton, Christopher I, et al. "FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13145
Milton CI, Selfe J, Aladowicz E, Man SYK, Bernauer C, Missiaglia E, Walters ZS, Gatz SA, Kelsey A, Generali M, Box G, Valenti M, de Haven-Brandon A, Galiwango D, Hayes A, Clarke M, Izquierdo E, Gonzalez De Castro D, Raynaud FI, Kirkin V, Shipley JM. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. Mol Oncol. 2021 Nov 30; doi: 10.1002/1878-0261.13145. Epub 2021 Nov 30. PMID: 34850536.
Copy
Download .nbib